Zinzino Reports 14% Revenue Growth in May 2026, Driven by Central Europe and North America
Event summary
- Zinzino's group revenue increased by 14% year-over-year to SEK 316.1 million in May 2026.
- Central Europe and North America showed significant growth, with 36% and 44% increases respectively.
- Year-to-date revenue for January-May 2026 rose by 23% to SEK 1,545.9 million.
- Faun Pharma's external sales remained flat at SEK 3.9 million.
- East Europe and the Baltics experienced declines, with -17% and -19% changes respectively.
The big picture
Zinzino's strong performance in May 2026 highlights its strategic focus on expanding in high-growth regions like Central Europe and North America. The company's ability to navigate regional disparities and leverage its direct-selling model will be crucial in maintaining its upward trajectory. The 23% year-to-date revenue growth underscores the effectiveness of its market strategies, but sustained execution will be key to solidifying its position in the competitive healthcare and nutritional supplements sector.
What we're watching
- Regional Performance
- How Zinzino will address declines in East Europe and the Baltics while sustaining growth in Central Europe and North America.
- Market Expansion
- Whether the 350% surge in South America can be maintained or replicated in other emerging markets.
- Operational Efficiency
- The pace at which Faun Pharma's sales can be integrated or accelerated to contribute more significantly to overall revenue.